Skip to main content

KRAS Activating Mutation clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for
  • Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

    Sorry, in progress, not accepting new patients

    This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

    San Francisco 5391959, California 5332921 and other locations

  • Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer

    Sorry, in progress, not accepting new patients

    This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.

    San Francisco 5391959, California 5332921 and other locations

Our lead scientists for KRAS Activating Mutation research studies include .

Last updated: